Lite Strategy LITS
NASDAQ LITS
$1.06 +0.00 (+0.00%)
At close: Sep 10, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Net Cash Flow (2010 - 2026)

Lite Strategy (LITS) posted Net Cash Flow of -$1.2 million for Q1 2026, up 10.41% on a QoQ basis from -$1.4 million in Q4 2025, and up 62.84% year-over-year from -$745514.7 in Q1 2025.

Analysis

Lite Strategy (LITS) Net Cash Flow (2010 - 2026) Analysis & Trends

Lite Strategy has reported Net Cash Flow for 17 years, with the latest figure at -$1.2 million in Q1 2026.

  • On a quarterly basis, Net Cash Flow rose 62.84% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was -$12.9 million, a 171.41% decrease from a year earlier, with the FY2025 full-year figure at $14.3 million, up 208.37% from the prior year.
  • Net Cash Flow was -$1.2 million for Q1 2026 at Lite Strategy, up from -$1.4 million in the prior quarter.
  • The five-year high for Net Cash Flow was $16.8 million in Q4 2024, with the low at -$13.5 million in Q3 2023.
  • Average Net Cash Flow over 5 years is -$294529.4, with a median of -$1.4 million recorded in 2025.
  • The sharpest annual moves came in 2023 and 2024: Net Cash Flow tumbled 1145.08% in 2023, then surged 831.58% in 2024.
  • Over 5 years, Net Cash Flow stood at -$3.7 million in 2022, then surged by 148.23% to $1.8 million in 2023, then soared by 831.58% to $16.8 million in 2024, then plunged by 108.07% to -$1.4 million in 2025, then gained by 10.41% to -$1.2 million in 2026.
  • The last three Net Cash Flow figures came in at -$1.2 million (Q1 2026), -$1.4 million (Q4 2025), and -$7.9 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Cash Flow (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 1.95 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn -4.43 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 652.90 Mn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn -504.30 Mn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn -183.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn -496,000.00
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn -2.09 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -170.75 Mn
10 Lite Strategy 38.03 Mn 30.49 Mn - -1.21 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.21 Mn
Dec 31, 2025 -1.36 Mn
Sep 30, 2025 -7.90 Mn
Jun 30, 2025 -2.46 Mn
Mar 31, 2025 -3.27 Mn
Dec 31, 2024 16.79 Mn
Sep 30, 2024 3.25 Mn
Jun 30, 2024 1.34 Mn
Mar 31, 2024 -2.81 Mn
Dec 31, 2023 1.80 Mn
Sep 30, 2023 -13.53 Mn
Jun 30, 2023 8.09 Mn
Mar 31, 2023 -2.11 Mn
Dec 31, 2022 -3.74 Mn
Sep 30, 2022 -1.09 Mn
Jun 30, 2022 4.63 Mn
Mar 31, 2022 -1.44 Mn
Dec 31, 2021 -3.07 Mn
Sep 30, 2021 7.08 Mn
Jun 30, 2021 -1.20 Mn